一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2024-047 号 一心堂药业集团股份有限公司 关于 2023 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司(以下简称"公司")于2024年4月26日召开第六届董事会第八 次会议，审议通过了《关于公司2023年度利润分配预案的议案》，现将该预案的基本情况公告 如下： 一、2023 年度利润分配预案的内容 经中审众环会计师事务所（特殊普通合伙）出具的标准无保留意见审计报告，公司 2023 年实现归属于上市公司股东的母公司净利润为 352,332,927.12 元。依据《公司法》和《公司章 程》等有关规定，2023 年度不提取法定盈余公积金，公司拟按以下方案实施分配： A、加年初未分配利润 2,786,713,022.38 元，减本年度已分配利润 238,409,370.00 元，2023 年度可供股东分配的利润为 2,900,636,579.50 元。 B、以未来实施分配方案时股权登记日的总股本为基数，向全体股东每 10 股派发现金红利 ...

一心堂药业集团股份有限公司内部控制规则落实自查表 | 内部控制规则落实自查事项 | 是/否/不适用 | 说明 | | --- | --- | --- | | 一、内部审计和审计委员会运作 | | | | 1、内部审计部门负责人是否为专职，并由审 | 是 | | | 计委员会提名，董事会任免。 | | | | 2、公司是否设立独立于财务部门的内部审计 | 是 | | | 部门，是否配置专职内部审计人员。 | | | | 3、内部审计部门是否至少每季度向审计委员 | 是 | | | 会报告一次。 | | | | 4、内部审计部门是否至少每季度对如下事项 | --- | --- | | 进行一次检查： | | | | （1）募集资金的存放与使用 | 是 | | | （2）对外担保 | 是 | | | （3）关联交易 | 是 | | | （4）证券投资 | 是 | | | （5）风险投资 | 是 | | | （6）对外提供财务资助 | 是 | | | （7）购买和出售资产 | 是 | | | （8）对外投资 | 是 | | | （9）公司大额资金往来 | 是 | | | （10）公司与董事、监事、高级管理人员、 控股 ...

Financial Performance - The company's revenue for Q1 2024 reached ¥5,099,517,768.62, representing a 14.96% increase compared to ¥4,435,751,548.19 in the same period last year[7] - Net profit attributable to shareholders was ¥241,918,445.99, a slight increase of 1.03% from ¥239,463,487.17 year-on-year[7] - The company reported a basic earnings per share of ¥0.4059, a 0.69% increase from ¥0.4031 in the same period last year[7] - The total equity attributable to the parent company increased to CNY 7.99 billion in Q1 2024, up from CNY 7.75 billion in the previous year[80] - The total comprehensive income for the quarter was ¥246,310,583.84, compared to ¥243,083,624.94 in the previous year, reflecting a growth of about 1.0%[82] Cash Flow and Assets - The net cash flow from operating activities increased by 41.72% to ¥521,470,407.90, up from ¥367,952,024.17 in the previous year[7] - Cash and cash equivalents increased by 372.86% to ¥293,130,877.46, compared to ¥61,990,565.75 in the previous year[13] - As of the end of the reporting period, the company's cash and cash equivalents amounted to approximately CNY 3.91 billion, an increase from CNY 3.68 billion at the beginning of the period, reflecting a growth of about 6.2%[53] - The total assets at the end of the reporting period were ¥17,540,627,932.34, reflecting a 5.37% growth from ¥16,647,375,283.89 at the end of the previous year[7] - The company's long-term liabilities, including lease liabilities, amounted to ¥1,626,600,594.98, up from ¥1,552,169,653.05, reflecting an increase of about 4.5%[54] Store Expansion and Operations - The number of stores increased to 10,746, with 579 new stores opened in Q1 2024[19] - The company reported a total of 10,746 self-operated chain stores by the end of the reporting period, indicating a robust growth in store count[63] - In Q1 2024, Yixintang's store count in Hainan reached nearly 500, covering 18 counties and over 70 townships, following the acquisition of 71 stores from Yuan'anlong Supermarket[66] - The company aims to enhance the operational efficiency and service quality of existing stores while expanding its network, focusing on internal growth potential[62] Research and Development - The company’s research and development expenses increased by 70.83% to approximately ¥2.83 million, reflecting higher capitalized R&D expenditures[31] - Research and development expenses for the quarter amounted to ¥2,834,665.49, up from ¥1,659,313.40, marking an increase of approximately 70.6%[89] Community and Health Initiatives - Membership in Hainan province surpassed 4 million, driven by various marketing and community engagement activities, including 1,062 health community events[23] - The company has served over 470 children through its child growth and development management project in 2023, showcasing its commitment to community health initiatives[45] - The company is actively exploring the integration of elderly care and medical services, establishing a comprehensive ecosystem for elderly care across the province[45] - The health management sector is shifting focus from treatment and rehabilitation to disease prevention, aligning with national health goals[93] Inventory and Receivables - The company reported a significant increase in accounts receivable, rising by 36.68% to approximately ¥1.96 billion due to increased wholesale business sales[31] - The company's accounts receivable increased to approximately CNY 1.96 billion, up from CNY 1.44 billion, indicating a growth of about 36.4%[53] - The inventory balance rose to approximately CNY 3.97 billion, compared to CNY 3.85 billion at the beginning of the period, representing an increase of about 3.5%[53] Strategic Focus and Partnerships - The company is leveraging its brand and human resources advantages in Yunnan to expand into diversified businesses, including healthcare and community services[40] - The company has formed strategic partnerships with various personal care and health food suppliers, improving product variety and sales growth in Yunnan Province[41] - The company aims to deepen its focus on traditional Chinese medicine, enhancing the entire industry and supply chain from planting to customer delivery[47] Marketing and Sales Growth - The company is actively exploring online business opportunities, leveraging its store network and brand influence to enhance e-commerce sales[87] - The company plans to leverage social media and short video platforms for effective promotion and customer education of general health categories[94] - Cross-industry collaborations with beauty, personal care, and food brands are expected to create additional growth opportunities and enhance product offerings[94] Operational Efficiency - The company’s logistics and operational efficiency improved with the establishment of a modern logistics and training center in Hainan, operational since 2021[23] - Yixintang is optimizing its logistics and terminal response speed through advanced logistics management systems, improving efficiency in product delivery[64] - The company aims to optimize low-contribution stores through digital tools and operational management techniques to enhance profitability[40]

章程 | | | 2024 年 4 月 26 日 一心堂药业集团股份有限公司 | 第一章 | 总则 2 | | --- | --- | | | 第二章经营宗旨和范围 3 | | | 第三章股份 4 | | 第一节 | 股份发行 4 | | | 第二节股份增减和回购 6 | | | 第三节股份转让 7 | | 第四章 | 股东和股东大会 8 | | | 第一节股东 8 | | | 第二节股东大会的一般规定 10 | | | 第三节股东大会的召集 12 | | 第四节 | 股东大会的提案与通知 13 | | 第五节 | 股东大会的召开 15 | | | 第六节股东大会的表决和决议 17 | | 第五章 | 董事会 21 | | | 第一节董事 21 | | 第二节 | 独立董事 24 | | | 第三节董事会 26 | | 第四节 | 董事会秘书 31 | | | 第六章 总裁及其他高级管理人员 31 | | 第七章 | 监事会 33 | | | 第一节监事 33 | | | 第二节监事会 33 | | 第八章 | 财务会计制度、利润分配和审计 36 | | | 第一节财务会计制度 36 | | 第二节 | 利润 ...

一心堂药业集团股份有限公司 2023年度独立董事陈旭东述职报告 作为一心堂药业集团股份有限公司（以下简称"公司"）的独立董事，本人按 照《公司法》《证券法》《上市公司独立董事管理办法》《深圳证券交易所上市公 司自律监管指引第1号——主板上市公司规范运作》《公司独立董事工作制度》及《公 司章程》等法律法规的规定和要求，忠实、谨慎、勤勉履职，依法行使独立董事的 权利，报告期内认真审议各项议案，客观发表自己观点和意见，利用专业知识作出 独立、公正的判断，促进公司的规范运作，切实维护公司和全体股东特别是中小股 东的合法权益。现将本人2023年度任职内履职情况报告如下： 一、独立董事的基本情况 （一）工作履历、专业背景以及兼职情况 本人陈旭东，中国国籍，无永久境外居留权。1963年12月出生，学士，1990年 至2023年在云南财经大学工作,任云南财经大学会计学院教授。中国会计学会资深会 员,曾任云南省司法鉴定人协会专业委员会委员，自2022年11月18日起担任公司第六 届董事会独立董事及提名委员会主席、审计委员会委员，现兼任云南驰宏锌锗股份 有限公司独立董事和建设工业集团（云南）股份有限公司独立董事。 （二）独立性情 ...

Financial Performance - The company's operating revenue for 2023 was ¥17,380,310,852.71, a decrease of 0.29% compared to ¥17,431,615,604.10 in 2022[3] - Net profit attributable to shareholders for 2023 was ¥549,441,525.99, down 45.60% from ¥1,009,996,157.90 in 2022[3] - The net profit after deducting non-recurring gains and losses was ¥732,513,463.32, a decrease of 25.94% compared to ¥989,137,722.83 in 2022[3] - The net cash flow from operating activities was ¥2,115,339,452.09, down 15.29% from ¥2,497,100,478.58 in 2022[3] - Basic earnings per share for 2023 were ¥0.9207, a decline of 45.91% from ¥1.7022 in 2022[3] - The weighted average return on equity was 6.97% in 2023, down from 14.47% in 2022, a decrease of 7.50%[5] - The retail segment generated revenue of approximately ¥12.63 billion, a decrease of 7.00% compared to the same period last year, with a gross margin of 37.97%[56] - The wholesale segment achieved revenue of approximately ¥3.90 billion, an increase of 17.51% year-over-year, with a gross margin of 12.32%[56] - The company’s e-commerce sales reached ¥876 million in 2023, with O2O channel sales accounting for approximately 74%[47] - The company reported a total of 10,255 stores at the end of the reporting period, with 1,381 new stores opened and 134 closed, reflecting a net increase in store count[46] Asset Management - Total assets at the end of 2023 were ¥16,647,375,283.89, an increase of 2.89% from ¥16,179,093,228.09 at the end of 2022[5] - Net assets attributable to shareholders at the end of 2023 were ¥7,745,981,105.08, up 4.31% from ¥7,426,145,337.11 at the end of 2022[5] - As of December 31, 2023, cash and cash equivalents amounted to ¥3,675,634,469.23, representing 22.08% of total assets, an increase of 0.38% from the beginning of the year[99] - Accounts receivable decreased to ¥1,436,843,216.82, accounting for 8.63% of total assets, down by 2.05% compared to the start of the year[99] - Inventory increased to ¥3,852,555,670.82, making up 23.14% of total assets, up by 2.20% from the beginning of the year[99] Strategic Initiatives - The company is focusing on expanding its prescription drug market and enhancing cooperation with brand enterprises and original research drug manufacturers[14] - The company aims to improve its supply chain management and establish long-term strategic partnerships with well-known pharmaceutical manufacturers and wholesalers[14] - The company has rapidly developed stores across four market types: provincial, municipal, county, and town, establishing a three-dimensional direct sales development pattern[15] - The company emphasizes a deep and strong development strategy in provincial markets, enhancing brand influence and competitive ability in county markets[15] - The online sales network is being actively constructed, with significant growth potential in the pharmaceutical e-commerce market as consumer awareness of online purchasing increases[17] - The company plans to implement a comprehensive marketing strategy that includes seasonal and thematic marketing activities to attract diverse consumer segments[20] - The company is focusing on building a standardized and comprehensive flagship store model across different regions to enhance customer experience and operational resilience[15] - The company is leveraging advanced information systems for real-time inventory management and inter-store collaboration to optimize operational efficiency[15] - The company continues to implement a "high-density network in fewer regions" strategy, achieving leading brand and market share in multiple regional markets, with profitability continuously improving[33] Customer Engagement and Services - The company aims to enhance its product offerings by meeting diverse customer medication needs through a multi-category approach[18] - The company is committed to improving product quality through various measures, including the "Starry Sky Plan" for training and knowledge sharing[22] - The company is enhancing its training system to improve core competencies of staff, focusing on store manager development to elevate service levels and customer satisfaction[37] - The company is focusing on chronic disease management by establishing specialized pharmacy service areas and providing health measurement services[148] - The company has developed a customer relationship management system to provide in-depth services for chronic disease management and maternal and infant care[63] - The company is focusing on digitalization and intelligent health services to meet evolving market demands[63] - The company has segmented its customer base into various groups, including chronic disease patients and young consumers, to provide tailored services[63] - The company is committed to building a comprehensive health service platform that offers personalized health consultations and disease prevention services[63] Digital Transformation and Innovation - The company has implemented a five-year digital construction plan to enhance core competitiveness and optimize business processes[61] - The company has established a research and development center focused on digital product development, with several products already in use[61] - The company is actively developing digital capabilities and e-commerce strategies to enhance market coverage and profitability[159] - The company has launched the "Yixin Daojia" O2O business mini-program to integrate online and offline operations, enhancing its e-commerce ecosystem[136] - The new retail segment will focus on empowering the main business for high-quality development, utilizing big data and AI to enhance online and offline service efficiency, aiming for a more effective reach to consumers[34] Compliance and Governance - The company is committed to maintaining a strong regulatory compliance environment, which benefits well-compliant and high-credit chain pharmacy enterprises[30] - The company reported administrative penalties totaling CNY 34.99 million over the past three years, representing 0.0020% of total revenue[187] - The company has not engaged in any entrusted financial management or loans during the reporting period[184][185] - The company did not report any significant differences in net profit or net assets between international and Chinese accounting standards during the reporting period[100][101] Fundraising and Investment - The total amount raised from the convertible bonds issuance was RMB 60,263.92 million, with a net amount of RMB 59,603.54 million after deducting fees[169] - As of December 31, 2023, the company had used RMB 5,094.11 million of the raised funds, totaling RMB 12,018.20 million used cumulatively[169] - The remaining balance of the raised funds as of December 31, 2023, was RMB 50,619.54 million, including interest and investment income[169] - The company temporarily supplemented working capital with RMB 45,000 million of idle raised funds in 2022, which was fully returned within the stipulated 12 months[169] - Interest and investment income from the raised funds amounted to RMB 3,034.20 million as of December 31, 2023[169] - The company has consistently ensured that the use of raised funds does not deviate from the original investment projects[169] Market Expansion - The company is expanding its market presence in Southwest and South China while strengthening its competitive capabilities in core regions[44] - The company aims to expand its market presence in South China and North China, enhancing its market share in the Southwest region[65] - The company has established health management centers and plans to offer online appointment services for patients[148] - The company has expanded its product offerings in health and beauty, achieving sales of ¥370 million in 2023, with beauty products making up 60% of this category[49] - The company initiated a "pharmacy + lottery" business pilot in 8 provinces/cities, generating lottery sales of ¥76.98 million in 2023[50] Operational Efficiency - The logistics center supports long-term stable development, with a central warehouse and 12 provincial warehouses, efficiently handling various business types and achieving industry-leading operational efficiency[42] - The company has upgraded its information processing systems, including WMS and ERP, significantly improving operational efficiency and achieving integrated management of supply chain processes[43] - The logistics center has implemented semi-automated management, significantly improving logistics efficiency and accuracy, while ensuring product quality through temperature and humidity monitoring systems[161] - The average daily revenue per square meter across all stores is 37.09 RMB, with a rental efficiency of 22.6 times annual sales to rent[68] Shareholder Information - The company plans to distribute a cash dividend of 4 RMB per 10 shares to all shareholders, with no bonus shares issued[139] - The total number of restricted shares before the changes was 596,070,525, which decreased to 596,023,425 after the cancellation of 47,100 shares[199] - The total number of shares with unlimited sale conditions was 398,318,708, representing 66.82% of the total shares before the changes[196] - After the changes, the total number of shares with unlimited sale conditions increased to 399,972,383, which is 67.11% of the total shares[196]

内部控制审计报告 众环审字（2024）1600090 号 一心堂药业集团股份有限公司 内部控制审计报告 众环审字（2024）1600090 号 目录 页码 内部控制审计报告 1-2 一心堂药业集团股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审计了一心 堂药业集团股份有限公司（以下简称"一心堂公司"）2023 年 12 月 31 日的财务报告内部控制的有 效性。 一、一心堂公司对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指引》的 规定，建立健全和有效实施内部控制，并评价其有效性是一心堂公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审计意见，并 对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于情况的变化可 能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内部控制审计结果推 测未来内部控制的有效性具有一定风险。 审计报告第 1 页共 2 页 四、财务报 ...

一心堂药业集团股份有限公司 董事会审计委员会对会计师事务所 2023 年度履行监督职责情况的报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理 准则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运 作》和《公司章程》《董事会审计委员会工作细则》等相关规定，一心堂药业集 团股份有限公司（以下简称"公司"）董事会审计委员会本着勤勉尽责的原则， 恪尽职守，认真履职。现将董事会审计委员会对会计师事务所 2023 年度履行监 督职责的情况报告如下： 一、2023 年年审会计师事务所基本情况 （一）会计师事务所基本情况 1、基本信息 （1）机构名称：中审众环会计师事务所（特殊普通合伙）（以下简称"中 审众环"） （2）成立日期：中审众环始创于 1987 年，是全国首批取得国家批准具有从 事证券、期货相关业务资格及金融业务审计资格的大型会计师事务所之一。根据 财政部、证监会发布的从事证券服务业务会计师事务所备案名单，本所具备股份 有限公司发行股份、债券审计机构的资格。2013 年 11 月，按照国家财政部等有 关要求转制为特殊普通合伙制。 （3）组织形式：特殊普通合伙企业 （4） ...

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2024-051 号 一心堂药业集团股份有限公司 关于召开 2023 年年度股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司(以下简称"公司")于 2024 年 4 月 26 日召开第六届董事会 第八次会议，会议决议于 2024 年 5 月 21 日下午 14 时在公司会议室召开公司 2023 年年度股东 大会，本次股东大会采用现场投票与网络投票相结合的方式召开，现将本次会议的有关事项通 知如下： 一、召开会议的基本情况 1、股东大会届次：2023 年年度股东大会 2、会议召集人：公司第六届董事会 3、会议召开的合法、合规性：公司第六届董事会第八次会议审议通过了《关于召开 2023 年年度股东大会的议案》。公司董事会召集本次股东大会会议符合有关法律、行政法规、部门 规章、规范性文件和《公司章程》的相关规定。 4、会议召开的日期和时间： （1）现场会议召开时间：2024 年 5 月 21 日（星期二）下午 14 点； （2）网络投票时间：2024 年 ...

一心为民 全心服务 第六届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 一心堂药业集团股份有限公司(以下简称"公司")第六届董事会第八次会议于2024年4月26 日10时以现场及通讯表决方式在公司会议室召开，本次会议于2024年4月15日通过邮件及书面形 式发出通知。本次会议应出席会议的董事为9人，实际出席会议的董事为9人。公司监事及非董 事高级管理人员列席了会议。本次会议的召开符合有关法律、行政法规、部门规章、规范性文 件和《公司章程》的规定。 会议由阮鸿献先生主持。与会董事逐项审议了有关议案并做出决议如下。 二、董事会会议审议情况 1、审议通过《关于公司 2023 年年度报告全文及摘要的议案》 《公司2023年年度报告全文》详见公司指定信息披露媒体巨潮资讯网（www.cninfo.com.cn）。 并批准2023年财务报告对外报出。 股票代码：002727 股票简称：一心堂 公告编号：2024-043 号 一心堂药业集团股份有限公司 《2023 年年度报告摘要》详见公司指定信息披露媒体《证券时报》、《中国 ...